Amgen rStock Valued at ₹1.015M with Strong Regulatory Moats
Amgen rStock is a pioneering global biotechnology leader that specializes in the discovery, development, and high-volume manufacturing of human genetics-based biologics. The company has dominant therapeutic portfolios in bone health (Prolia), cardiovascular conditions (Repatha), and biosimilars. Amgen's strong regulatory moats and steady cross-cycle pricing power make it a highly defensive income-generating pharma asset.
The market capitalization of Amgen rStock is ₹1.015M, indicating that the asset is highly valued by the market. The trading volume over the last 24 hours was ₹36.163K. Assets with similar market caps include RoboStrategy Inc aStock, GeneDx Holdings Corp aStock, and C3.ai Inc aStock.
Amgen rStock has a circulating supply of 28 units. The asset's price history shows that it has maintained its value over the past year, with a one-year price change of ₹36,628.05. It is essential to note that Amgen rStock is not suitable for all investors, and potential buyers should conduct thorough research before making any investment decisions.